Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine
Research Institute for Biological Safety Problems
Abstract
The study is a single centre, phase I, double-blind, randomized, placebo-controlled trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21) TB/FLU-04L tuberculosis vaccine versus matched placebo in BCG-vaccinated healthy adult subjects aged 18-50 years.
MeSH terms
- Tuberculosis